Herzuma® (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe
The Mundipharma global network of independent associated companies today announced that Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months. The Mundipharma network has exclusive distribution rights to Herzuma in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.
Richard Trollope, Head of Oncology and Biosimilars at Mundipharma International Limited, said: “Building on our partnership with Celltrion Healthcare, we are pleased to announce that biosimilar trastuzumab is now available in Europe with national launches commencing in both the UK and Germany. The availability of biosimilar trastuzumab will provide an alternative treatment option to the thousands of eligible patients across Europe with early breast cancer, metastatic breast cancer or metastatic gastric cancer.”
Herzuma, a biosimilar of i.v. Herceptin®, was granted marketing authorisation on 9th February 2018 for the treatment of patients with early breast cancer, metastatic breast cancer or metastatic gastric cancer whose tumours have either HER2 overexpression or HER2 gene amplification, following positive opinion and recommendation for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2017. Biosimilar trastuzumab has the potential to make significant cost savings for healthcare organisations, releasing healthcare resource for other innovative medicines.3
Alberto Martinez, President and CEO, Mundipharma International Limited, said: “Mundipharma has a proven track record of launching biosimilars successfully in Europe, which is illustrated by Celltrion Healthcare entrusting us once again with the launch of biosimilar trastuzumab across key European markets. As biosimilar trastuzumab continues to launch in additional countries, we look forward to assisting healthcare economies across Europe wanting to deliver better value to patients.”
Herzuma is the third biosimilar to be marketed and distributed by the Mundipharma network in Europe, having launched Remsima ® (infliximab), the first biosimilar monoclonal antibody, in 2015, and Truxima® (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in 2017.
Notes to editors:
About the Mundipharma network
The Mundipharma global network of privately-owned independent associated companies, including Napp Pharmaceuticals Ltd in the UK, was founded in 1956 by doctors and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.
For more information please visit: www.mundipharma.com.
Trastuzumab is a monoclonal antibody designed to target the HER2 receptor. When it binds to the receptor, trastuzumab reduces HER2 signalling that otherwise increases tumour stimulation, and also enables the immune system to target the cancerous tumour.4
It is administered on its own as monotherapy, as well as in combination with or following standard chemotherapy. Trastuzumab has changed the prognosis of patients with HER2 positive breast cancer, both in advanced and early stage disease.5
Biosimilar is a term used to describe officially approved subsequent versions of biopharmaceutical medicines that are made available by a different company following patent and exclusivity expiry on the original product. Biosimilars are classed as biologic medical products, which mean they contain an active drug substance that is comprised of, or derived from, a living organism. Biosimilars are strictly regulated and need to demonstrate comparability to the previously approved reference product via a thorough development programme including quality assurance, pre-clinical and clinical programmes.
®Herzuma is a registered trade mark of Celltrion, Inc. and is used under licence.
®Herceptin is a registered trade mark of Genentech, Inc.
1 Herceptin (trasutuzmab) Summary of Product Characteristics. Available online at: https://www.medicines.org.uk/emc/medicine/3567. Accessed April 2018
2 Herzuma (trastutuzmab) Summary of Product Characteristics. Available at: https://ec.europa.eu/health/documents/community-register/2018/20180209139854/anx_139854_en.pdf - Accessed April 2018
3 Delivering on the Potential of Biosimilar Medicines. March 2016. Available online at: https://www.coursehero.com/file/20466083/IMS-Institute-Biosimilar-Brief-March-2016/. Accessed April 2018
4 Gajria D, et al. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer ther. 2011 Fe: 11 (2): 263-275
5 Bartsch, R et al. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007; 1(1): 19–31
Communications Lead for Mundipharma
Telephone: +44 (0) 1223 397 3361
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Utimaco Cleared to Complete Acquisition of Atalla16.10.2018 06:55 | Pressemelding
Utimaco, the second largest global provider of Hardware Security Modules (HSMs) today announced it has received United States regulatory approval to complete its acquisition of the Atalla Hardware Security Module (HSM) and Enterprise Secure Key Manager (ESKM) business lines of Micro Focus. The transaction is due to close on November 5, 2018. “This is a significant milestone, and we look forward to bringing the Atalla team under the information security umbrella of Utimaco. After several changes of ownership, we are happy to offer Atalla a long-term home in our HSM and information security business,” said Utimaco CEO, Malte Pollmann. Read more: https://hsm.utimaco.com/news/utimaco-cleared-to-complete-acquisition-of-atalla About Utimaco Utimaco is a worldwide supplier of professional information security solutions and is based in Aachen, Germany with offices worldwide. Since 1983, Utimaco has been developing hardware-based, high-security appliances (Hardware Security Modules) and complia
PM Studios Partners with The Playgroundz Foundation to Develop New Blockchain Project16.10.2018 06:52 | Pressemelding
Software development and video game publisher PM Studios, partnered with the Playgroundz Foundation to help in the development of a new blockchain project. Playgroundz is best described as a “Google” for videogames. It is a platform for videogames and game related services. Playgroundz will be a gateway to a videogame database where developers and gamers can come and virtually do anything game related. We are simply creating a new gaming ecosystem where everything videogame related is decentralized and belongs solely to the players and developers. Playgroundz consists of an AI system, which takes advantage of Big Data and Machine Learning to specifically analyze the traits of users, Marketplace, which utilize Blockchain and Smart Contract in order to make Escrows safe and transparent, and Rewarded Community System, which is based on loyalty users. Based on optimized Machine Learning Algorithm, the analyzed data recommends users with new games, matches users automatically with buyer or
Kongsberg Digital and Alibaba Cloud to Explore Opportunities for Digitalizing the Energy Sector in China16.10.2018 06:06 | Pressemelding
China has taken a global number one position when it comes to investing in renewable energy sources. Digitalization is high on the country’s agenda when it comes to increased efficiency and transformed business models. To further promote that development, Kongsberg Digital and Alibaba Cloud, the cloud computing arm of Alibaba Group, have signed a memorandum of understanding (MoU) to explore the opportunities provided by making KONGSBERG’s industrial digital platform, Kognifai, available on Alibaba Cloud’s infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015006030/en/ Simon Hu, Senior Vice President of Alibaba Group and President of Alibaba Cloud, and Hege Skryseth, Executive Vice President of KONGSBERG and President of Kongsberg Digital, signed an MoU to explore the opportunities to make KONGSBERG's industrial digital platform, Kognifai, available on Alibaba Cloud (Photo: Business Wire) “Bringing Kognifai to
GE’s AffinityTM: The first civil supersonic engine in 55 years – launching a new era of efficient supersonic flight15.10.2018 22:17 | Pressemelding
At a press conference with Aerion Corporation today, GE Aviation announced that it has completed the initial design of the first supersonic engine purpose-built for business jets. This new engine class, revealed today as GE’s AffinityTM turbofan, is optimized with proven GE technology for supersonic flight and timed to meet the Aerion AS2 launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005961/en/ The name “Affinity” was chosen because it reflects this engine class’ harmonious assemblage of GE’s commercial, non-civil and business aviation propulsion technologies to bring a true step-change in commercial supersonic propulsion. (Photo: Business Wire) The Affinity is a new class of medium bypass ratio engines that provide exceptional and balanced performance across supersonic and subsonic flights. The Affinity integrates a unique blend of proven military supersonic experience, commercial reliability and the most adv
IFF to Release Third Quarter 2018 Results November 515.10.2018 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its third quarter 2018 earnings results following the market close on Monday, November 5, 2018. The management team will host a live webcast on Tuesday, November 6, 2018 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for
Sumitomo SHI FW Wins Contract for Biomass CFB Boiler Island in South Korea15.10.2018 20:00 | Pressemelding
Sumitomo SHI FW (SFW) announces today that it has been awarded a contract by SK Engineering & Construction Co., Ltd. for design and supply of SMG Energy’s SMG Biomass Power Plant to be located in Gunsan City in the Republic of Korea. Commercial operation of the new plant is scheduled for December 2020. SFW will design and supply the 100 MWe CFB steam generator and auxiliary equipment for the boiler island. The CFB steam generator will be designed to burn 100% wood pellets, while meeting applicable environmental regulatory requirements. SFW has supplied over 30 CFB steam generators to South Korea and this is the fourth firing biomass as its primary fuel. Tomas Harju-Jeanty, CEO, Sumitomo SHI FW, said: “Both higher efficiency and the use of biomass in power generation can contribute significantly to reducing emissions of carbon dioxide. SFW’s CFB technology is a perfect solution to meet these market requirements. We are pleased to again be chosen to play a part in helping South Korea mee